Long-acting parenteral drug delivery systems for the treatment of chronic diseases

Jindal, Anil; Bhide, Atharva R; Salave, Sagar; Benival, Derajram

doi:10.1016/j.addr.2023.114862

Cited by 34 publications

(9 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While delayed release is challenging to achieve in parenteral models, alternative routes, such as intramuscular, transdermal, or implantation, allow for innovation in design, considering the limited dosage. Limited drug load and the necessity for controlled release further complicate the design, requiring innovative solutions for dosing with burst release for the initial and maintenance doses to preserve therapeutic effects ( Jindal et al, 2023 ).…”

Section: Liposome Modification For Antimalarial Drug Deliverymentioning

confidence: 99%

Advancing liposome technology for innovative strategies against malaria

Miatmoko,

Octavia,

Araki

et al. 2024

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Section: Liposome Modification For Antimalarial Drug Deliverymentioning

confidence: 99%

Advancing liposome technology for innovative strategies against malaria

Miatmoko,

Octavia,

Araki

et al. 2024

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

“…To improve the efficiency and effectiveness of PLGA-based drug delivery, it is crucial to thoroughly understand the factors that influence the degradation rate and drug release kinetics of PLGA-based polymers [ 263 ]. In addition to that, injection site reaction, accumulation of immune cells, and deposition of micro- and nanoparticles in the spleen and lung can pose significant challenges for developing polymeric nano- and microparticles [ 264 ].…”

Section: La Arv Deliverymentioning

confidence: 99%

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Nayan,

Panja,

Sultana

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

show abstract

“…[ 71 ] Moreover, the special slow‐release function of the microspheres gives the material the characteristics of continuous drug administration, which is facilitating the long‐term administration of severe or chronic wounds. [ 94 ]…”

Section: Forms Of Gag‐based Biomaterialsmentioning

confidence: 99%

“…Moreover, GAG‐based biomaterials possess a natural affinity for cells and biomolecules, which can aid in the efficient delivery and maintenance of active cargoes in vivo. [ 94 ] The GAG‐based microneedles are usually used for transdermal delivery of active substances to promote tissue regeneration. Owing to its exceptional biodegradability and bioactivities, [ 88 ] HA is frequently utilized in the production of soluble microneedles.…”

Section: Forms Of Gag‐based Biomaterialsmentioning

confidence: 99%

Glycosaminoglycans’ Ability to Promote Wound Healing: From Native Living Macromolecules to Artificial Biomaterials

Yang,

Lu,

Gou

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Glycosaminoglycans (GAGs) are important for the occurrence of signaling molecules and maintenance of microenvironment within the extracellular matrix (ECM) in living tissues. GAGs and GAG‐based biomaterial approaches have been widely explored to promote in situ tissue regeneration and repair by regulating the wound microenvironment, accelerating re‐epithelialization, and controlling ECM remodeling. However, most approaches remain unacceptable for clinical applications. To improve insights into material design and clinical translational applications, this review highlights the innate roles and bioactive mechanisms of native GAGs during in situ wound healing and presents common GAG‐based biomaterials and the adaptability of application scenarios in facilitating wound healing. Furthermore, challenges before the widespread commercialization of GAG‐based biomaterials are shared, to ensure that future designed and constructed GAG‐based artificial biomaterials are more likely to recapitulate the unique and tissue‐specific profile of native GAG expression in human tissues. This review provides a more explicit and clear selection guide for researchers designing biomimetic materials, which will resemble or exceed their natural counterparts in certain functions, thereby suiting for specific environments or therapeutic goals.

show abstract

Long-acting parenteral drug delivery systems for the treatment of chronic diseases

Cited by 34 publications

References 103 publications

Advancing liposome technology for innovative strategies against malaria

Advancing liposome technology for innovative strategies against malaria

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Glycosaminoglycans’ Ability to Promote Wound Healing: From Native Living Macromolecules to Artificial Biomaterials

Contact Info

Product

Resources

About